Description of secondary effects in users of the etonogestrel implant in Honduras from March 2017 to May 2018
DOI:
https://doi.org/10.35839/repis.4.3.602Keywords:
contraceptives, etonogestrel, implant, subdermal, secondary effectsAbstract
Introduction: The etonogestrel contraceptive implant is a modern method, which offers users contraceptive efficacy of up to 99% in a period of 3 years; it is safe comfortable and accessible. As all drugs have secondary effects, they are described as follows: amenorrhea, dysfunctional uterine bleeding, acne, nausea, and headache.
Objective: To determine which are the most frequent secondary effects in users of the etonogestrel subdermal implant, in Tegucigalpa Honduras, from March 2017 to May 2018. Material and method: Descriptive, cross-sectional study of implant users in a polyclinic in Tegucigalpa, Honduras. The sample included women of childbearing age who voluntarily applied for the contraceptive implant to use it for the first time; the inclusion criteria were: use of the etonogestrel implant as a contraceptive method.
Results: A total 115 women who met inclusion criteria were included. The most frequent secondary effect was amenorrhea, reported by 78 (68%), followed by headache 29 (25%), dysfunctional uterine bleeding 28 (24%), had other secondary effects such as weight gain, mastalgia, acne, nausea and others. Despite the secondary effects, 99 (86%) of women continue to use the implant and 109 (95%) of them would recommend it to other women for use as a contraceptive method.
Conclusion: The most frequent secondary effect in users of the etonogestrel implant is amenorrhea, followed by headache and dysfunctional uterine bleeding.
Downloads
References
Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs y Organización Mundial de la Salud. Organización Mundial de la Salud. Planificación familiar, un manual mundial para proveedores. Organización Mundial de la Salud [Internet] 2011. [citado 15 mayo 2020] Disponible en: https://www.who.int/reproductivehealth/publications/family_planning/9780978856304/es/
Ramdhan RC, Simonds E, Wilson C, et al. Complications of Subcutaneous Contraception: A Review. Cureus [Internet] 2018. [citado 15 mayo 2020] Vol. 10(1): e2132. DOI 10.7759/cureus.2132 Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/29610715
Calixto-Morales DP, Ospina-Díaz JM, Manrique-Abril FG. Retiro temprano del implante subdérmico con etonogestrel en usuarias de un programa de anticoncepción de Tunja - Boyacá, Colombia. Univ. Salud. [Internet] 2015. [citado 15 mayo 2020] Vol.17, No 2: 224-232. DOI:org/10.22267/rus.151702.7 Disponible en: https://revistas.udenar.edu.co/index.php/usalud/article/view/2709
Aisien, AO. Enosolease, ME. Safety, efficacy and acceptability of implanon a single rod implantable contraceptive (etonogestrel) in University of Benin Teaching Hospital. Niger J Clin Pract. [Internet] 2010 [Citado 15 mayo 2020] Vol.13, No.3:331-5 Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/20857796
Romano, M. Toye, P. Patchen , L. Continuation of long-acting reversible contraceptives among Medicaid patients. Contraception. [Internet] 2018 [citado 15 mayo 2020] Vol. 98, No.2:125-129 DOI: 10.1016/j.contraception.2018.04.012. Disponible en: https://www.contraceptionjournal.org/article/S0010-7824(18)30148-3/fulltext
Bahamondes, L. Brache V, Meirik O, Ali M, Habib N, Landoulsi S. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. Human Reproduction[Internet] 2015 Vol.30, No.11:2527–2538 DOI: 10.1093/humrep/dev221 Disponible en: https://academic.oup.com/humrep/article/30/11/2527/2384927
Orane, A. Sangrado uterino anormal. Rev Cl EMed UCR [Internet]. 2016 [Citado 16 mayo2020] Vol 6, No.6:11-20 Disponible en: https://www.medigraphic.com/pdfs/revcliescmed/ucr-2016/ucr164i.pdf
Sepúlveda-Agudelo J, Sepúlveda-Sanguino AJ. Sangrado uterino anormal y PALM COEIN. Ginecol Obstet Mex. [Internet] 2020 [Citado 16 mayo2020] Vol.88, No.1:59-67. DOI.org/10.24245/gom. v88i1.3467 Disponible en: https://www.medigraphic.com/pdfs/ginobsmex/gom-2020/gom201j.pdf
Sajid, D. Mehmood, T. Etonogestrel implant (Implanon) frequency of adverse effects caused by implantation of single rod etonogestrel implant in females seeking birth spacing after delivery of previous pregnancy. Professional Medical Journal [Internet] 2017 [Citado 16 mayo 2020] Vol. 24 No.5:685-689. DOI: 10.17957/TPMJ/17.3965 Disponible en: https://www.researchgate.net/publication/317377743_ETONOGESTREL_IMPLANT_IMPLANON_FREQUENCY_OF_ADVERSE_EFFECTS_CAUSED_BY_IMPLANTATION_OF_SINGLEROD_ETONOGESTREL_IMPLANT_IMPLANON_IN_FEMALES_SEEKING_BIRTH_SPACING_AFTER_DELIVERY_OF_PREVIOUS_PREGNANCY
Wahab Noraziana A, Rahman NA, Mustafa KB, Awang M, Sidek AA, Ros RM. A clinical evaluation of bleeding patterns, adverse effects, and satisfaction with the subdermal etonogestrel implant among postpartum and non-postpartum users. Int J Gynaecol Obstet. [Inernet] 2016 [Citado 16 mayo 2020] Vol.132, No.2:237-8.
DOI: 10.1016/j.ijgo.2015.07.022. Disponible en: https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1016/j.ijgo.2015.07.022
Peterson AM, Brown A, Savage A, Dempsey A. Prevalence of early discontinuation and associated factors among a retrospective cohort of etonogestrel contraceptive implant users. Eur J Contracept Reprod Health Care. [Internet] 2019 [Citado 16 mayo 2020] Vol.24, No.6:475-479. DOI:10.1080/13625187.2019.1666361. Disponible en: https://www.tandfonline.com/doi/abs/10.1080/13625187.2019.1666361?journalCode=iejc20
Calixto-Morales DP, Ospina-Díaz JM, Manrique-Abril FG. Retiro temprano del implante subdérmico con etonogestrel en usuarias de un programa de anticoncepción de Tunja - Boyacá, Colombia. Univ. Salud. [Internet] 2015. [Citado 15 mayo 2020] Vol.17, No 2: 224-232. DOI:org/10.22267/rus.151702.7 Disponible en: https://revistas.udenar.edu.co/index.php/usalud/article/view/2709
Aziz MM, El-Gazzar AF, Elgibaly O. Factors associated with first-year discontinuation of Implanon in Upper Egypt: clients and providers perspectives. BMJ Sexual & Reproductive Health [Internet] 2018 [Citado 16 mayo 2020] Vol. 44:260-266. DOI: 10.1136/bmjsrh-2017-101860 Disponible en: https://srh.bmj.com/content/44/4/260
Leal I, Molina T, Montero A, Gonzalez C. Efectos secundarios en adolescentes chilenas usuarias de implante anticonceptivo subdérmico de etonogestrel. Matronas Prof. [Internet] 2016 [Citado 16 mayo 2020] Vol.17, No.4:137-142. Disponible en: https://www.cemera.cl/publicaciones/revistas/internacionales/1internacional%20Efectos%20secundarios.pdf
Diedrich JT, Klein DA, Peipert JF. Long-acting reversible contraception in adolescents: a systematic review and meta-analysis. Am J Obstet Gynecol. [Internet] 2017 [Citado 16 mayo 2020] Vol.216, No.4:364.e1-364.e12. DOI:10.1016/j.ajog.2016.12.024. Disponible en: https://scholarworks.iupui.edu/handle/1805/14931
Nageso A, Gebretsadik A. Discontinuation rate of Implanon and its associated factors among women who ever used Implanon in Dale District, Southern Ethiopia. BMC Womens Health. [Internet] 2018 [Citado 16 mayo 2020] Vol.20;18(1):189. DOI: 10.1186/s12905-018-0678-x Disponible en: https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-018-0678-x
Mansour D, Fraser IS, Edelman A. et al. Can initial vaginal bleeding patterns in etonogestrel implant users predict subsequent bleeding in the first 2 years of use? Contraception. [Internet] 2019 Vol.100, No. 4:264-268. DOI.org/10.1016/j.contraception.2019.05.017 Disponible en: https://www.contraceptionjournal.org/article/S0010-7824(19)30193-3/fulltext
Published
Issue
Section
How to Cite
.png)
